Physician profile
Hardik Doshi
NPI 1689929523
$4,894.50
in general payments reported to CMS, 2019-2025
27 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $248 · 2021: $1,037 · 2022: $471 · 2023: $275 · 2024: $2,172 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560 · Travel and Lodging: $1,017 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.23 |
| Travel and Lodging | $1,017.27 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,362.49 | 2024 | |
| Sk Life Science, INC. | $1,153.24 | 2020-2025 | Xcopri |
| Ucb, INC. | $646.05 | 2019-2024 | Briviact, Fintepla |
| Neurelis, INC. | $232.00 | 2024-2025 | Valtoco |
| Eisai INC. | $206.28 | 2019-2022 | |
| Livanova USA, INC. | $128.90 | 2019-2022 | |
| Allergan, INC. | $113.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $111.71 | 2019-2021 | |
| Biogen, INC. | $103.72 | 2019-2023 | Vumerity |
| Alexion Pharmaceuticals, INC. | $100.00 | 2024 | Ultomiris |
| Abbvie INC. | $94.43 | 2020-2024 | |
| Lilly USA, LLC | $93.33 | 2019-2023 | Emgality, Reyvow |
| Acadia Pharmaceuticals INC | $88.95 | 2019-2021 | |
| Emd Serono, INC. | $88.45 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $63.70 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $56.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $45.85 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $29.39 | 2019-2020 | |
| Amgen INC. | $25.72 | 2021 | |
| Genentech USA, INC. | $24.70 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.68 | 2020 | |
| Tanabe Pharma America, INC. | $21.68 | 2022 | |
| Genzyme Corporation | $20.06 | 2021 | |
| Portola Pharmaceuticals, LLC | $16.84 | 2019 | |
| Abbott Laboratories | $16.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.84 | 2021 | |
| Sumitomo Pharma America, INC. | $11.60 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardik Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.